PL3057589T3 - (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie - Google Patents

(S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie

Info

Publication number
PL3057589T3
PL3057589T3 PL14726444T PL14726444T PL3057589T3 PL 3057589 T3 PL3057589 T3 PL 3057589T3 PL 14726444 T PL14726444 T PL 14726444T PL 14726444 T PL14726444 T PL 14726444T PL 3057589 T3 PL3057589 T3 PL 3057589T3
Authority
PL
Poland
Prior art keywords
pirlindole
medicine
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
PL14726444T
Other languages
English (en)
Inventor
Filipe Augusto Eugénio Pardal
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
João Carlos Damil
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of PL3057589T3 publication Critical patent/PL3057589T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)
PL14726444T 2014-05-09 2014-05-09 (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie PL3057589T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14726444.4A EP3057589B1 (en) 2014-05-09 2014-05-09 (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PCT/PT2014/000029 WO2015171005A1 (en) 2014-05-09 2014-05-09 (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine

Publications (1)

Publication Number Publication Date
PL3057589T3 true PL3057589T3 (pl) 2018-01-31

Family

ID=50819931

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14726444T PL3057589T3 (pl) 2014-05-09 2014-05-09 (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie

Country Status (29)

Country Link
US (1) US9814712B2 (pl)
EP (1) EP3057589B1 (pl)
JP (1) JP6768520B2 (pl)
KR (1) KR102298676B1 (pl)
CN (1) CN106456637B (pl)
AU (1) AU2014393490B2 (pl)
CA (1) CA2948598C (pl)
CY (1) CY1119532T1 (pl)
DK (1) DK3057589T3 (pl)
EC (1) ECSP16086247A (pl)
ES (1) ES2649492T3 (pl)
HR (1) HRP20171651T1 (pl)
HU (1) HUE035071T2 (pl)
IL (1) IL248855B (pl)
LT (1) LT3057589T (pl)
MA (1) MA39447B1 (pl)
MX (1) MX368734B (pl)
NO (1) NO3057589T3 (pl)
NZ (1) NZ726132A (pl)
PH (1) PH12016502233A1 (pl)
PL (1) PL3057589T3 (pl)
PT (1) PT3057589T (pl)
RS (1) RS56591B1 (pl)
RU (1) RU2695647C2 (pl)
SA (1) SA516380264B1 (pl)
SI (1) SI3057589T1 (pl)
TN (1) TN2016000498A1 (pl)
UA (1) UA118474C2 (pl)
WO (1) WO2015171005A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3054950T3 (en) * 2014-05-09 2017-11-06 Tecnimede-Sociedade Tecnico-Medicinal S A (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
CA2948595C (en) * 2014-05-09 2021-07-13 Tecnimede Sociedade Tecnico-Medicinal S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
EP3392250A1 (en) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of piperazine ring for the synthesis of pyrazinocarbazole derivatives
EP3392251A1 (en) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of pirlindole enantiomers and its salts
MX2018011142A (es) 2018-09-13 2019-10-10 Federico Amezcua Amezcua Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
EP3900716A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Co-crystal of gabapentin, ketoprofen and lysine, pharmaceutical compositions and their medical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030633A2 (en) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
BR0317747A (pt) * 2002-12-24 2005-11-22 Neurochem Int Ltd Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
US20070043030A1 (en) * 2003-09-15 2007-02-22 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
CA2948595C (en) * 2014-05-09 2021-07-13 Tecnimede Sociedade Tecnico-Medicinal S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine

Also Published As

Publication number Publication date
CY1119532T1 (el) 2018-03-07
SI3057589T1 (sl) 2017-12-29
CN106456637A (zh) 2017-02-22
IL248855B (en) 2020-05-31
LT3057589T (lt) 2017-11-27
JP2017518979A (ja) 2017-07-13
KR102298676B1 (ko) 2021-09-07
US9814712B2 (en) 2017-11-14
PT3057589T (pt) 2017-11-29
MX368734B (es) 2019-10-14
ECSP16086247A (es) 2017-02-24
MA39447B1 (fr) 2018-05-31
ES2649492T3 (es) 2018-01-12
MX2016014699A (es) 2017-05-02
UA118474C2 (uk) 2019-01-25
CA2948598C (en) 2021-06-08
NO3057589T3 (pl) 2017-12-30
HRP20171651T1 (hr) 2017-12-15
HUE035071T2 (en) 2018-05-02
TN2016000498A1 (en) 2018-04-04
AU2014393490B2 (en) 2020-01-02
CN106456637B (zh) 2020-06-09
RU2016148183A3 (pl) 2018-06-13
RU2016148183A (ru) 2018-06-13
EP3057589A1 (en) 2016-08-24
KR20170002434A (ko) 2017-01-06
IL248855A0 (en) 2017-01-31
WO2015171005A1 (en) 2015-11-12
EP3057589B1 (en) 2017-08-02
RU2695647C2 (ru) 2019-07-25
MA39447A1 (fr) 2017-10-31
JP6768520B2 (ja) 2020-10-14
AU2014393490A1 (en) 2016-11-24
US20170143709A1 (en) 2017-05-25
DK3057589T3 (da) 2017-11-13
SA516380264B1 (ar) 2019-07-29
PH12016502233A1 (en) 2017-02-06
CA2948598A1 (en) 2015-11-12
RS56591B1 (sr) 2018-02-28
NZ726132A (en) 2019-02-22

Similar Documents

Publication Publication Date Title
PL3125883T3 (pl) Pochodne indolu do stosowania w medycynie
HK1244000B (zh) 多環氨基甲酰吡啶酮化合物及其藥物用途
IL248855B (en) S-pyralindole and its pharmaceutically acceptable salts for use in medicine
GB201617053D0 (en) A therapeutic agent for use in the treatment of infections
IL248854B (en) R-pyralindole and its pharmaceutically acceptable salts for use in medicine
GB201701400D0 (en) Compound for use in medicine
IL248852A0 (en) Pharmaceutically acceptable salts of pyrilindole enantiomers for use in medicine
GB201406115D0 (en) New pharmaceutical use
GB201616880D0 (en) Compound for use in medicine
GB201409662D0 (en) New pharmaceutical use
HRP20182167T1 (hr) Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba
GB201701388D0 (en) Compound for use in medicine
TH1601006738A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
AP2016009517A0 (en) Indole derivatives for use in medicine
TH1601006737A (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค